As of 2025-09-16, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -10.26 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.59 USD, the upside of Relmada Therapeutics Inc is -745.07%.
Based on its market price of 1.59 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 745.07%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.26 - -10.26 | -10.26 | -745.07% |
| P/E | (37.17) - (38.77) | (38.46) | -2519.0% |
| DDM - Stable | (18.19) - (52.19) | (35.19) | -2313.0% |
| DDM - Multi | (19.64) - (44.00) | (27.18) | -1809.6% |
| Market Cap (mil) | 52.77 |
| Beta | 1.91 |
| Outstanding shares (mil) | 33.19 |
| Enterprise Value (mil) | 52.77 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.72% |
| Cost of Debt | 5.00% |
| WACC | 6.69% |